Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Publisher Correction: 3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification.

Kalinin AA, Allyn-Feuer A, Ade A, Fon GV, Meixner W, Dilworth D, Husain SS, de Wet JR, Higgins GA, Zheng G, Creekmore A, Wiley JW, Verdone JE, Veltri RW, Pienta KJ, Coffey DS, Athey BD, Dinov ID.

Sci Rep. 2018 Oct 26;8(1):16142. doi: 10.1038/s41598-018-33574-w.

2.

3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification.

Kalinin AA, Allyn-Feuer A, Ade A, Fon GV, Meixner W, Dilworth D, Husain SS, de Wet JR, Higgins GA, Zheng G, Creekmore A, Wiley JW, Verdone JE, Veltri RW, Pienta KJ, Coffey DS, Athey BD, Dinov ID.

Sci Rep. 2018 Sep 12;8(1):13658. doi: 10.1038/s41598-018-31924-2. Erratum in: Sci Rep. 2018 Oct 26;8(1):16142.

3.

Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem.

Frost JJ, Pienta KJ, Coffey DS.

Oncotarget. 2017 Dec 5;9(14):11429-11440. doi: 10.18632/oncotarget.22939. eCollection 2018 Feb 20.

4.

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).

Hamdouchi C, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Eessalu TE, Ficorilli JV, Marcelo MC, Otto KA, Wilbur KL, Lineswala JP, Piper JL, Coffey DS, Sweetana SA, Haas JV, Brooks DA, Pratt EJ, Belin RM, Deeg MA, Ma X, Cannady EA, Johnson JT, Yumibe NP, Chen Q, Maiti P, Montrose-Rafizadeh C, Chen Y, Reifel Miller A.

J Med Chem. 2016 Dec 22;59(24):10891-10916. doi: 10.1021/acs.jmedchem.6b00892. Epub 2016 Nov 11.

PMID:
27749056
5.

Interprofessional Education of Health Professionals: Social Workers Should Lead the Way.

Taylor LD, Coffey DS, Kashner TM.

Health Soc Work. 2016 Feb;41(1):5-8. No abstract available.

PMID:
26946880
6.

Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.

Jadhav PK, Schiffler MA, Gavardinas K, Kim EJ, Matthews DP, Staszak MA, Coffey DS, Shaw BW, Cassidy KC, Brier RA, Zhang Y, Christie RM, Matter WF, Qing K, Durbin JD, Wang Y, Deng GG.

ACS Med Chem Lett. 2014 Aug 27;5(10):1138-42. doi: 10.1021/ml500283g. eCollection 2014 Oct 9.

7.

Evolution: Back to the future to understand and control prostate cancer.

Coffey DS.

Asian J Urol. 2014 Oct;1(1):4-11. doi: 10.1016/j.ajur.2014.09.007. Epub 2015 Apr 16. No abstract available.

8.

Niche inheritance: a cooperative pathway to enhance cancer cell fitness through ecosystem engineering.

Yang KR, Mooney SM, Zarif JC, Coffey DS, Taichman RS, Pienta KJ.

J Cell Biochem. 2014 Sep;115(9):1478-85. doi: 10.1002/jcb.24813.

9.

The cancer diaspora: Metastasis beyond the seed and soil hypothesis.

Pienta KJ, Robertson BA, Coffey DS, Taichman RS.

Clin Cancer Res. 2013 Nov 1;19(21):5849-55. doi: 10.1158/1078-0432.CCR-13-2158. Epub 2013 Oct 7. Review.

10.

Gleason score 6 adenocarcinoma: should it be labeled as cancer?

Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, Singer EA, Epstein JI.

J Clin Oncol. 2012 Dec 10;30(35):4294-6. doi: 10.1200/JCO.2012.44.0586. Epub 2012 Oct 1. No abstract available.

11.

Bacterial survival strategies suggest rethinking cancer cooperativity.

Ben-Jacob E, Coffey DS, Levine H.

Trends Microbiol. 2012 Sep;20(9):403-10. doi: 10.1016/j.tim.2012.06.001. Epub 2012 Jun 29.

PMID:
22750098
12.

Changing the energy habitat of the cancer cell in order to impact therapeutic resistance.

Getzenberg RH, Coffey DS.

Mol Pharm. 2011 Dec 5;8(6):2089-93. doi: 10.1021/mp200310u. Epub 2011 Sep 29. Review.

13.

Challenges in clinical prostate cancer: role of imaging.

Kelloff GJ, Choyke P, Coffey DS; Prostate Cancer Imaging Working Group.

AJR Am J Roentgenol. 2009 Jun;192(6):1455-70. doi: 10.2214/AJR.09.2579.

14.

Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect".

Coffey DS, Getzenberg RH, DeWeese TL.

JAMA. 2006 Jul 26;296(4):445-8. Review. No abstract available.

PMID:
16868303
15.

Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist.

Bueno AB, Collado I, de Dios A, Domínguez C, Martín JA, Martín LM, Martínez-Grau MA, Montero C, Pedregal C, Catlow J, Coffey DS, Clay MP, Dantzig AH, Lindstrom T, Monn JA, Jiang H, Schoepp DD, Stratford RE, Tabas LB, Tizzano JP, Wright RA, Herin MF.

J Med Chem. 2005 Aug 11;48(16):5305-20.

PMID:
16078848
16.

A conversation between Darracott Vaughan and Donald S. Coffey.

Coffey DS.

BJU Int. 2004 Oct;94(6):753-4. No abstract available.

17.

Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.

Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, Soule HR, D'Amico AV.

Clin Cancer Res. 2004 Jun 1;10(11):3927-33. Review. No abstract available.

18.

Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.

Kelloff GJ, Bast RC Jr, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF.

Clin Cancer Res. 2004 Jun 1;10(11):3881-4. Review. No abstract available.

19.
20.

Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.

Faul MM, Engler TA, Sullivan KA, Grutsch JL, Clayton MT, Martinelli MJ, Pawlak JM, LeTourneau M, Coffey DS, Pedersen SW, Kolis SP, Furness K, Malhotra S, Al-awar RS, Ray JE.

J Org Chem. 2004 Apr 30;69(9):2967-75.

PMID:
15104433
21.

Connection and autonomy in the case management relationship.

Coffey DS.

Psychiatr Rehabil J. 2003 Spring;26(4):404-12.

PMID:
12739911
22.

Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer.

Leman ES, Madigan MC, Brünagel G, Takaha N, Coffey DS, Getzenberg RH.

J Cell Biochem. 2003 Feb 15;88(3):599-608.

PMID:
12532335
23.

Understanding the cancer biology universe: enigmas, context and future prospects.

Coffey DS.

Cancer Biol Ther. 2002 Sep-Oct;1(5):564-7. No abstract available.

PMID:
12496490
25.

Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

Lupold SE, Hicke BJ, Lin Y, Coffey DS.

Cancer Res. 2002 Jul 15;62(14):4029-33. Erratum in: Cancer Res. 2012 Aug 1;72(15):3887.

26.

Training the urologic scientist---an endangered species.

Coffey DS.

Urology. 2002 Mar;59(3):315-7. No abstract available.

PMID:
11880060
27.

High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells.

Takaha N, Hawkins AL, Griffin CA, Isaacs WB, Coffey DS.

Cancer Res. 2002 Feb 1;62(3):647-51.

28.

New insights and methodologies are needed to solve the many epidemiologic enigmas of prostate cancer.

Coffey DS.

Epidemiol Rev. 2001;23(1):1. No abstract available.

PMID:
11588831
29.

Similarities of prostate and breast cancer: Evolution, diet, and estrogens.

Coffey DS.

Urology. 2001 Apr;57(4 Suppl 1):31-8.

PMID:
11295592
30.

Foreword

Coffey DS.

Prostate Suppl. 2000;9:1. No abstract available.

PMID:
11056494
31.

Morris Pollard: a pioneer in developing animal models for prostate cancer.

Coffey DS.

Prostate. 2000 Jun 1;43(4):245-6. No abstract available.

PMID:
10861741
32.

Gerald P. Murphy 1934-2000

Coffey DS.

Prostate. 2000 Apr;43(1):1-2. No abstract available.

PMID:
10725859
33.

Future prospects in prostate cancer.

Hegarty NJ, Fitzpatrick JM, Richie JP, Scardino PT, deVere White RW, Schröder FH, Coffey DS.

Prostate. 1999 Sep 1;40(4):261-8. Review.

PMID:
10420155
34.

The real final exam.

Coffey DS.

Prostate. 1999 Jun 1;39(4):323-5. No abstract available.

PMID:
10344224
35.

New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia.

De Marzo AM, Coffey DS, Nelson WG.

Urology. 1999 Mar;53(3 Suppl 3a):29-39; discussion 39-42. Review.

PMID:
10094098
36.

Stem cell features of benign and malignant prostate epithelial cells.

De Marzo AM, Nelson WG, Meeker AK, Coffey DS.

J Urol. 1998 Dec;160(6 Pt 2):2381-92. Review.

PMID:
9817389
37.
38.

Familial study of prostate cancer in Jamaica.

Glover FE Jr, Coffey DS, Douglas LL, Russell H, Cadigan M, Tulloch T, Wedderburn K, Wan RL, Baker TD, Walsh PC.

Urology. 1998 Sep;52(3):441-3.

PMID:
9730457
39.

Self-organization, complexity and chaos: the new biology for medicine.

Coffey DS.

Nat Med. 1998 Aug;4(8):882-5. No abstract available.

PMID:
9701230
40.

The epidemiology of prostate cancer in Jamaica.

Glover FE Jr, Coffey DS, Douglas LL, Cadogan M, Russell H, Tulloch T, Baker TD, Wan RL, Walsh PC.

J Urol. 1998 Jun;159(6):1984-6; discussion 1986-7.

PMID:
9598503
41.

Controversies in the management of lower urinary tract symptoms: an overview.

Coffey DS.

Br J Urol. 1998 Mar;81 Suppl 1:1-5; discussion 64-6. Review. No abstract available.

PMID:
9589010
42.

Telomerase: a promising marker of biological immortality of germ, stem, and cancer cells. A review.

Meeker AK, Coffey DS.

Biochemistry (Mosc). 1997 Nov;62(11):1323-31. Review.

PMID:
9467857
43.

Do bone marrow endothelial cells have specific house numbers, and how is this involved in metastasis?

Coffey DS.

J Natl Cancer Inst. 1998 Jan 21;90(2):84-5. No abstract available.

PMID:
9450561
44.

Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.

Partin AW, Briggman JV, Subong EN, Szaro R, Oreper A, Wiesbrock S, Meyer J, Coffey DS, Epstein JI.

Urology. 1997 Nov;50(5):800-8.

PMID:
9372899
45.

The concept of evolution in the pathogenesis and treatment of prostate cancer.

Garcia-Schurmann M, Coffey DS.

Br J Urol. 1997 Apr;79 Suppl 2:9-17. Review. No abstract available.

PMID:
9126065
46.

The Cost of Biological Terrorism.

Coffey DS.

Oncologist. 1997;2(6):XI-XII.

PMID:
10388077
47.

Prostate cancer metastasis: talking the walk.

Coffey DS.

Nat Med. 1996 Dec;2(12):1305-6. No abstract available.

PMID:
8946822
48.

Telomerase is activated in the prostate and seminal vesicles of the castrated rat.

Meeker AK, Sommerfeld HJ, Coffey DS.

Endocrinology. 1996 Dec;137(12):5743-6.

PMID:
8940411
49.
50.

Chaotic oscillations in cultured cells: rat prostate cancer.

Posadas EM, Criley SR, Coffey DS.

Cancer Res. 1996 Aug 15;56(16):3682-8.

Supplemental Content

Loading ...
Support Center